

Supplementary material for:  
Evaluation of an *In-Silico* Cardiac Safety Assay:  
Using Ion Channel Screening Data to Predict QT  
Interval Changes in the Rabbit Ventricular Wedge

Kylie A. Beattie, Chris Luscombe, Geoff Williams, Jordi Munoz-Muriedas,  
David J. Gavaghan, Yi Cui, Gary R. Mirams

April 8, 2013

## Contents

<b>S</b>	<b>Supplementary Material</b>	<b>1</b>
S.1	Downloading Datasets and Simulation Software . . . . .	1
S.2	Additional Results . . . . .	2
S.2.1	Further Combinations of Ion Channel Data Use . . . . .	2
S.2.2	Performance-Related Metrics Calculated For 44 Com- pounds With Data from Each Ion Channel Assay . . . . .	5
S.3	Experimental Protocols Used For Ion Channel Screening . . . . .	10
S.3.1	Screening using IonWorks . . . . .	10
S.3.2	CaV1.2 FLIPR Screen . . . . .	14
S.3.3	Screening using PatchXpress . . . . .	15

## <sup>1</sup> S Supplementary Material

### <sup>2</sup> S.1 Downloading Datasets and Simulation Software

<sup>3</sup> All of the datasets and simulation software used in this study are publically  
<sup>4</sup> available to download from [www.cs.ox.ac.uk/chaste/download](http://www.cs.ox.ac.uk/chaste/download).

<sup>5</sup> **S.2 Additional Results**

<sup>6</sup> **S.2.1 Further Combinations of Ion Channel Data Use**

Table S1: Prolongation metric values calculated (with 95% confidence intervals indicated) for evaluation of the assay’s predictivity of QT prolongation in the rabbit ventricular wedge experiments when considering the different uses of the available ion channel data described which were not included in the main text. Entries are ordered alphabetically by the data type used in the simulations.

Case Number	Ion Channel Data Use Combination	Accuracy (%)	Kappa Value	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
S1	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value (121 Compounds)	<b>65.3</b> (56.5-73.2)	<b>0.35</b> (0.19-0.51)	<b>89.2</b> (75.3-95.7)	<b>54.8</b> (44.1-65.0)	<b>46.5</b> (35.4-58.0)	<b>92.0</b> (81.2-96.8)
S2	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient (121 Compounds)	<b>66.1</b> (57.3-73.9)	<b>0.36</b> (0.20-0.52)	<b>89.2</b> (75.3-95.7)	<b>56.0</b> (45.3-66.1)	<b>47.1</b> (35.9-58.7)	<b>92.2</b> (81.5-96.9)
S3	IonWorks/FLIPR Data, Multiple Channel Block Including KCNQ1 Interactions, Fitting For IC <sub>50</sub> Value & Hill Coefficient (121 Compounds)	<b>75.2</b> (66.8-82.0)	<b>0.46</b> (0.29-0.63)	<b>73.0</b> (57.0-84.6)	<b>76.2</b> (66.1-84.0)	<b>57.4</b> (43.3-70.5)	<b>86.5</b> (76.9-92.5)
S4	PatchXpress Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient (77 Compounds)	<b>71.4</b> (60.5-80.3)	<b>0.47</b> (0.28-0.66)	<b>100</b> (86.7-100)	<b>57.7</b> (44.2-70.1)	<b>53.2</b> (39.2-66.7)	<b>100</b> (88.6-100)
S5	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient, One-Dimensional Simulation (77 Compounds)	<b>70.1</b> (59.2-79.2)	<b>0.41</b> (0.21-0.61)	<b>84.0</b> (65.3-93.6)	<b>63.5</b> (49.9-75.2)	<b>52.5</b> (37.5-67.1)	<b>89.2</b> (75.3-95.7)
S6	QSAR Data, hERG Block Only (372 Compounds)	<b>54.6</b> (49.5-59.6)	<b>0.16</b> (0.07-0.26)	<b>94.4</b> (89.8-97.1)	<b>23.8</b> (18.6-30.0)	<b>48.9</b> (43.4-54.4)	<b>84.7</b> (73.5-91.8)

Table S2: Shortening metric values calculated (with 95% confidence intervals indicated) for evaluation of the assay’s predictivity for QT shortening in the rabbit ventricular wedge experiments considering the different uses of available ion channel data described which were not included in the main text. Entries are ordered alphabetically by the data type used in the simulations. Missing entries are due to the inability to calculate the metrics due to there being no compounds in the relevant categories for their computation.

Case Number	Ion Channel Data Use Combination	Accuracy (%)	Kappa Value	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
S1	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value (121 Compounds)	<b>74.4</b> (65.9-81.3)	<b>0.00</b> (-0.30-0.30)	<b>0.00</b> (0.00-11.0)	<b>100</b> (95.9-100)	-	<b>74.4</b> (65.9-81.3)
S2	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient (121 Compounds)	<b>74.4</b> (65.9-81.3)	<b>0.00</b> (-0.30-0.30)	<b>0.00</b> (0.00-11.0)	<b>100</b> (95.9-100)	-	<b>74.4</b> (65.9-81.3)
S3	IonWorks/FLIPR Data, Multiple Channel Block Including KCNQ1 Interactions, Fitting For IC <sub>50</sub> Value & Hill Coefficient (121 Compounds)	<b>71.1</b> (62.4-78.4)	<b>0.22</b> (0.00-0.44)	<b>38.7</b> (23.7-56.2)	<b>82.2</b> (73.1-88.8)	<b>42.9</b> (29.8-57.0)	<b>79.6</b> (70.3-86.5)
S4	PatchXpress Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient (77 Compounds)	<b>76.6</b> (66.0-84.7)	<b>0.00</b> (-0.40-0.40)	<b>0.00</b> (0.00-17.6)	<b>100</b> (93.9-100)	-	<b>76.6</b> (66.0-84.7)
S5	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient, One-Dimensional Simulation (77 Compounds)	<b>74.0</b> (63.3-82.5)	<b>0.27</b> (0.00-0.55)	<b>44.4</b> (24.6-66.3)	<b>83.1</b> (71.5-90.5)	<b>44.4</b> (30.2-59.6)	<b>83.1</b> (71.5-90.5)
S6	QSAR Data, hERG Block Only (372 Compounds)	<b>82.8</b> (78.6-86.3)	<b>0.00</b> (-0.22-0.22)	<b>0.00</b> (0.00-5.66)	<b>100</b> (98.8-100)	-	<b>82.8</b> (78.6-86.3)

<sup>7</sup> **S.2.2 Performance-Related Metrics Calculated For 44 Compounds**  
<sup>8</sup> **With Data from Each Ion Channel Assay**

Table S3: Prolongation metric values calculated (with 95% confidence intervals indicated) for evaluation of the assay’s predictivity of QT prolongation in the rabbit ventricular wedge experiments when considering the different uses of the available ion channel data described for a subset of 44 compounds for which there were ion channel data available from all three assays. Entries are ordered alphabetically by the data type used in the simulations.

Case Number	Ion Channel Data Use Combination	Accuracy (%)	Kappa Value	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
S1	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>72.7</b> (58.2-83.7)	<b>0.47</b> (0.22-0.73)	<b>92.9</b> (68.5-98.7)	<b>63.3</b> (45.5-78.1)	<b>54.2</b> (35.1-72.1)	<b>95.0</b> (76.4-99.1)
S2	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient (44 Compounds)	<b>72.7</b> (58.2-83.7)	<b>0.47</b> (0.22-0.73)	<b>92.9</b> (68.5-98.7)	<b>63.3</b> (45.5-78.1)	<b>54.2</b> (35.1-72.1)	<b>95.0</b> (76.4-99.1)
S3	IonWorks/FLIPR Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>81.8</b> (68.0-90.5)	<b>0.60</b> (0.34-0.85)	<b>78.6</b> (52.4-92.4)	<b>83.3</b> (66.4-92.7)	<b>68.8</b> (44.4-85.8)	<b>89.3</b> (72.8-96.3)
S4	IonWorks/FLIPR Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient (44 Compounds)	<b>77.3</b> (63.0-87.2)	<b>0.50</b> (0.22-0.77)	<b>71.4</b> (45.4-88.3)	<b>80.0</b> (62.7-90.5)	<b>62.5</b> (38.6-81.5)	<b>85.7</b> (68.5-94.3)
S5	IonWorks/FLIPR Data, Multiple Channel Block Including KCNQ1 Interactions, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>79.5</b> (65.5-88.8)	<b>0.55</b> (0.29-0.81)	<b>78.6</b> (52.4-92.4)	<b>80.0</b> (62.7-90.5)	<b>64.7</b> (41.3-82.7)	<b>88.9</b> (71.9-96.1)
S6	IonWorks/FLIPR Data, Multiple Channel Fitting For IC <sub>50</sub> Value & Hill Coefficient Including KCNQ1 Interactions (44 Compounds)	<b>77.3</b> (63.0-87.2)	<b>0.50</b> (0.22-0.77)	<b>71.4</b> (45.4-88.3)	<b>80.0</b> (62.7-90.5)	<b>62.5</b> (38.6-81.5)	<b>85.7</b> (68.5-94.3)
S7	PatchXpress Data, hERG Block Only, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>77.3</b> (63.0-87.2)	<b>0.56</b> (0.32-0.80)	<b>100</b> (78.5-100)	<b>66.7</b> (48.8-80.8)	<b>58.3</b> (38.8-75.5)	<b>100</b> (83.9-100)

S8	PatchXpress Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient (44 Compounds)	<b>75.0</b> (60.6-85.4)	<b>0.52</b> (0.28-0.77)	<b>100</b> (78.5-100)	<b>63.3</b> (45.5-78.1)	<b>56.0</b> (37.1-73.3)	<b>100</b> (83.2-100)
S9	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>70.5</b> (55.8-81.8)	<b>0.33</b> (0.03-0.64)	<b>57.1</b> (32.6-78.6)	<b>76.7</b> (59.1-88.2)	<b>53.3</b> (30.1-75.2)	<b>79.3</b> (61.6-90.2)
S10	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient (44 Compounds)	<b>75.0</b> (60.6-85.4)	<b>0.45</b> (0.18-0.73)	<b>71.4</b> (45.4-88.3)	<b>76.7</b> (59.1-88.2)	<b>58.8</b> (36.0-78.4)	<b>85.2</b> (67.5-94.1)
S11	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value, One-Dimensional Simulation (44 Compounds)	<b>68.2</b> (53.4-80.0)	<b>0.38</b> (0.12-0.65)	<b>85.7</b> (60.1-96.0)	<b>60.0</b> (42.3-75.4)	<b>50.0</b> (31.4-68.6)	<b>90.0</b> (69.9-97.2)
S12	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient, One-Dimensional Simulation (44 Compounds)	<b>63.6</b> (48.9-76.2)	<b>0.32</b> (0.05-0.58)	<b>85.7</b> (60.1-96.0)	<b>53.3</b> (36.1-69.8)	<b>46.2</b> (28.8-64.5)	<b>88.9</b> (67.2-96.9)
S13	QSAR Data, hERG Block Only (44 Compounds)	<b>50.0</b> (35.8-64.2)	<b>0.19</b> (-0.05-0.43)	<b>100</b> (78.5-100)	<b>26.7</b> (14.2-44.4)	<b>38.9</b> (24.8-55.1)	<b>100</b> (67.6-100)
S14	QSAR Data, Multiple Channel Block (44 Compounds)	<b>54.5</b> (40.1-68.3)	<b>0.24</b> (0.00-0.49)	<b>100</b> (78.5-100)	<b>33.3</b> (19.2-51.2)	<b>41.2</b> (26.4-57.8)	<b>100</b> (72.2-100)

Table S4: Shortening metric values calculated (with 95% confidence intervals indicated) for evaluation of the assay’s predictivity for QT shortening in the rabbit ventricular wedge experiments considering the different uses of available ion channel data described for a subset of 44 compounds for which there were data available from all three assays. Entries are ordered alphabetically by the data type used in the simulations. Missing entries are due to the inability to calculate the metrics due to there being no compounds in the relevant categories for their computation.

Case Number	Ion Channel Data Use Combination	Accuracy (%)	Kappa Value	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
S1	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>77.3</b> (63.0-87.2)	<b>0.00</b> (-0.54-0.54)	<b>0.00</b> (0.00-27.8)	<b>100</b> (89.8-100)	-	<b>77.3</b> (63.0-87.2)
S2	IonWorks Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient (44 Compounds)	<b>77.3</b> (63.0-87.2)	<b>0.00</b> (-0.54-0.54)	<b>0.00</b> (0.00-27.8)	<b>100</b> (89.8-100)	-	<b>77.3</b> (63.0-87.2)
S3	IonWorks/FLIPR Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>70.5</b> (55.8-81.8)	<b>0.13</b> (-0.27-0.53)	<b>30.0</b> (10.8-60.3)	<b>82.4</b> (66.5-91.7)	<b>33.3</b> (15.6-57.6)	<b>80.0</b> (64.1-90.0)
S4	IonWorks/FLIPR Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient (44 Compounds)	<b>72.7</b> (58.2-83.7)	<b>0.27</b> (-0.08-0.62)	<b>50.0</b> (23.7-76.3)	<b>79.4</b> (63.2-89.7)	<b>41.7</b> (21.5-65.0)	<b>84.4</b> (68.2-93.1)
S5	IonWorks/FLIPR Data, Multiple Channel Block Including KCNQ1 Interactions, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>70.5</b> (55.8-81.8)	<b>0.13</b> (-0.27-0.53)	<b>30.0</b> (10.8-60.3)	<b>82.4</b> (66.5-91.7)	<b>33.3</b> (15.9-56.9)	<b>80.0</b> (64.1-90.0)
S6	IonWorks/FLIPR Data, Multiple Channel Block Including KCNQ1 Interactions, Fitting For IC <sub>50</sub> Value & Hill Coefficient (44 Compounds)	<b>70.5</b> (55.8-81.8)	<b>0.19</b> (-0.18-0.56)	<b>40.0</b> (16.8-68.7)	<b>79.4</b> (63.2-89.7)	<b>36.4</b> (17.7-60.3)	<b>81.8</b> (65.6-91.4)
S7	PatchXpress Data, hERG Block Only, Fitting For IC <sub>50</sub> Value (44 Compounds)	<b>77.3</b> (63.0-87.2)	<b>0.00</b> (-0.54-0.54)	<b>0.00</b> (0.00-27.8)	<b>100</b> (89.8-100)	-	<b>77.3</b> (63.0-87.2)



S8	PatchXpress Data, hERG Block Only, Fitting For IC <sub>50</sub> Value & Hill Coefficient ( <i>44</i> <i>Compounds</i> )	<b>77.3</b> (63.0-87.2)	<b>0.00</b> (-0.54-0.54)	<b>0.00</b> (0.00-27.8)	<b>100</b> (89.8-100)	-	<b>77.3</b> (63.0-87.2)
S9	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value ( <i>44 Compounds</i> )	<b>79.5</b> (65.5-88.8)	<b>0.23</b> (-0.22-0.68)	<b>20.0</b> (5.67-51.0)	<b>97.1</b> (85.1-99.5)	<b>66.7</b> (41.7-84.8)	<b>80.5</b> (66.0-89.8)
S10	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient ( <i>44 Compounds</i> )	<b>77.3</b> (63.0-87.2)	<b>0.18</b> (-0.27-0.63)	<b>20.0</b> (5.67-51.0)	<b>94.1</b> (80.9-98.4)	<b>50.0</b> (28.5-71.5)	<b>80.0</b> (65.2-89.5)
S11	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value, One-Dimensional Simulation ( <i>44 Compounds</i> )	<b>72.7</b> (58.2-83.7)	<b>0.10</b> (-0.34-0.53)	<b>20.0</b> (5.67-51.0)	<b>88.2</b> (73.4-95.3)	<b>33.3</b> (18.0-53.3)	<b>78.9</b> (63.7-88.9)
S12	PatchXpress Data, Multiple Channel Block, Fitting For IC <sub>50</sub> Value & Hill Coefficient, One-Dimensional Simulation ( <i>44 Compounds</i> )	<b>75.0</b> (60.6-85.4)	<b>0.20</b> (-0.20-0.61)	<b>30.0</b> (10.8-60.3)	<b>88.2</b> (73.4-95.3)	<b>42.9</b> (26.0-61.6)	<b>81.1</b> (65.8-90.5)
S13	QSAR Data, hERG Block Only ( <i>44 Compounds</i> )	<b>77.3</b> (63.0-87.2)	<b>0.00</b> (-0.54-0.54)	<b>0.00</b> (0.00-27.8)	<b>100</b> (89.8-100)	-	<b>77.3</b> (63.0-87.2)
S14	QSAR Data, Multiple Channel Block ( <i>44 Compounds</i> )	<b>68.2</b> (53.4-80.0)	<b>-0.05</b> (-0.51-0.40)	<b>10.0</b> (1.79-40.4)	<b>85.3</b> (69.9-93.6)	<b>16.7</b> (7.70-32.4)	<b>76.3</b> (60.8-87.0)

## 9 S.3 Experimental Protocols Used For Ion Channel Screening

### 10 S.3.1 Screening using IonWorks

#### 11 Cell Preparation

##### 12 Human NaV1.5:

13 Human Embryonic Kidney-293 (HEK293) cells were stably transfected with  
14 human NaV1.5 expression vector (pCIN5-hNaV1.5). Cells were cultured in  
15 DMEM with F12, supplemented with 10% FBS, 1x NEAA, plus 400 $\mu$ g/ml  
16 geneticin. Cells were grown and maintained at 37°C in a humidified environ-  
17 ment containing 5% CO<sub>2</sub>. Media without geneticin was used for cell har-  
18 vesting. Cells with less than 80% confluency were detached from the T75  
19 culture flask for passage and harvesting using TrypLE or Versene. After  
20 media aspiration cells were washed with pre-warmed Ca<sup>2+</sup>- and Mg<sup>2+</sup>-free  
21 D-PBS. Then 3 ml pre-warmed TrypLE or Versene were added for 3-5 min-  
22 utes, respectively, followed by addition of 10-12 ml pre-warmed Ca<sup>2+</sup>- and  
23 Mg<sup>2+</sup>-containing D-PBS. Finally cells were gently mixed 3-4 times. The  
24 suspension was centrifuged at 300 x G for 2 minutes, the pellet resuspended  
25 to a cell concentration of 2-3 million cells/ml and that solution added to  
26 the IonWorks™ instrument.

##### 27 hERG:

28 Chinese Hamster Ovary (CHO) cells stably expressing hERG were cultured  
29 in M1 DMEM Ham's with F12, supplemented with 10% FBS and 400 $\mu$ g/ml  
30 geneticin. Cells were thawed in T175 flasks at 6-8millions cells per T175  
31 flask, maintained at 37°C in a humidified environment containing 5% CO<sub>2</sub>  
32 for 3-4 hours and transferred to a 30°C incubator containing 5% CO<sub>2</sub> and  
33 incubate for another 72 hours before assaying. On day of assay, cells which  
34 were over 80% confluence were used. Media were removed and cells were  
35 washed with warm PBS (without magnesium and calcium) two times. 5 ml  
36 pre-warmed Versene was added for 6 minutes, followed by addition of 10  
37 ml of warm M1 media. The suspension was placed into a 15 ml centrifuge  
38 tube and spun for 2 minutes at 1K rpm. The supernatant was removed  
39 and cells were re-suspended in 5 ml of warm M1 media and incubated for  
40 5 minutes for the cells to recover. After 5 minutes the cells the suspension  
41 was centrifuged at 1K rpm for 2 minutes, the pellet re-suspended to a cell  
42 concentration of 4-5 million cells/ml and that solution was added to the  
43 IonWorks™.

44 KCNQ1:

45 Chinese hamster ovary (CHO) cells were stably transfected with KCNQ1  
46 (also known as Kv1.7 or KvLQT1) the pore forming unit of the cardiac  
47 potassium current inward rectifier -and KCNE1 (also known as minK) the  
48 auxiliary subunit in the cardiac ion channel. Cells were cultured in IMDM  
49 ISCOVE media, supplemented with 10% FBS and 800 $\mu$ g/ml geneticin, 1 ml  
50 hygromycin, 5 ml Pen/Strep and filtered. Cells were thawed in T175 flasks  
51 at 6-8 millions cells per T175 flask, maintained at 37°C in a humidified envi-  
52 ronment containing 5% CO<sub>2</sub> for 24 hours and transferred to a 30°C incubator  
53 containing 5% CO<sub>2</sub> and incubated for another 48 hours before assaying. On  
54 day of assay, confluency of cells should be < 40% for screening. Media were  
55 removed, and cells were washed with warm KCNQ1 external solution (with-  
56 out magnesium and calcium). 3 ml pre-warmed TrypLE was added for 2-3  
57 minutes, followed by addition of 10 ml of warm KCNQ1 external solution  
58 (without magnesium and calcium). The suspension was placed into a 15  
59 ml centrifuge tube and spun for 2 minutes at 1K rpm. The supernatant  
60 was removed and cells re-suspended in 5 ml of warm KCNQ1 external so-  
61 lution (with magnesium and calcium). The pellet was re-suspended to a  
62 cell concentration of 3.5-4.5 million cells/ml and that solution added to the  
63 IonWorks™.

#### 64 **Experimental Protocols**

65 All currents were recorded before and after the addition of compound using  
66 a Molecular Devices IonWorks Quattro automated electrophysiology instru-  
67 ment in Population Patch-Clamp mode.

68 Human NaV1.5:

69 The intracellular solution contained the following: 100 mM K-gluconate,  
70 40 mM KCl, 3.2 mM MgCl<sub>2</sub>, 5 mM HEPES, 3 mM EGTA, pH 7.3 with  
71 KOH. Amphotericin-B solution was prepared as 50 mg/ml stock solution in  
72 dimethylsulfoxide (DMSO) and diluted to a final working concentration of  
73 0.1 mg/ml in intracellular solution. The external solution was D-PBS and  
74 contained the following: 0.90 mM CaCl<sub>2</sub>, 2.67 mM KCl, 1.47 mM KH<sub>2</sub>PO<sub>4</sub>,  
75 0.493 mM MgCl<sub>2</sub>, 137.9 mM NaCl, 8.06 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.4. All wells  
76 with a pre- and post-drug addition resistance of > 20M $\Omega$  and which yielded  
77 a > 200pA transient inward NaV current were included in the analysis.

78 The voltage pulse protocol applied pre- and post- compound addition was  
79 as follows: From a holding potential of -80 mV (30 seconds), a train of  
80 five 200 millisecond depolarising voltage pulses were applied at a frequency

81 of 2 Hz. The peak of the inward currents during the first and fifth 0 mV  
82 depolarisation were exported for the pre- and post-drug conditions. The  
83 amount of compound block observed at the fifth pulse determines the accu-  
84 mulated block observed and is expressed a percentage of the pre-compound  
85 current observed at the first pulse to give a measure of the “global” (tonic  
86 and use-dependent) block achieved by the compound.

87 **hERG:**

88 The KCl intracellular solution contained the following: 140 mM KCl, 1 mM  
89 MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 20 mM HEPES, pH 7.3 with KOH. Amphotericin-  
90 B solution was prepared as 50 mg/ml stock solution in dimethylsulfoxide  
91 (DMSO) and diluted to a final working concentration of 0.1 mg/ml in intra-  
92 cellular solution. The external solution was D-PBS (-). The voltage pulse  
93 protocol applied pre- and post- compound addition was as follows: hERG  
94 currents were activated by 4 seconds depolarising pulse to +40 mV from a  
95 holding potential of -80 mV. The cells were then repolarised to -50 mV to  
96 generate large outward tail currents for 5 seconds.

97 **KCNQ1:**

98 The KCNQ1 internal solution contained the following: 100 mM Potassium  
99 Gluconate, 54 mM Potassium Chloride, 3.2 mM MgCl<sub>2</sub>, 5 mM HEPES, pH  
100 7.3 with KOH. All solutions were filtered before use. Amphotericin-B solu-  
101 tion was prepared as 50 mg/ml stock solution in dimethylsulfoxide (DMSO)  
102 and diluted to a final working concentration of 0.1 mg/ml in intracellular  
103 solution. The KCNQ1 external solution with Ca<sup>2+</sup> and Mg<sup>2+</sup> contained  
104 the following: 65 mM Sodium Gluconate, 70 mM Sodium Chloride, 5 mM  
105 Potassium Chloride, 0.5 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 5 mM HEPES, pH 7.4  
106 with NaOH. The KCNQ1 external solution without Ca<sup>2+</sup> and Mg<sup>2+</sup> con-  
107 tained the following: 65 mM Sodium Gluconate, 70 mM Sodium Chloride,  
108 5 mM Potassium Chloride, 5 mM HEPES, pH 7.4 with NaOH. The voltage  
109 pulse protocol applied pre- and post- compound addition was as follows:  
110 From a holding potential of -80 mV (100 ms), test opener potential 0 mV  
111 for 4 seconds, step to -10mV for 2 seconds, holding potential -80 mV for  
112 5 seconds, test blocker potential +50 mV for 4 seconds, step to -10 mV  
113 for 2 seconds. The amount of compound block observed at the end of the  
114 +50 mV pulse and is expressed a percentage of the pre-compound current  
115 observed at the beginning of the +50 mV pulse to give a measure of the  
116 tonic block achieved by the compound.

117 **Data Analysis**

118 IonWorks recordings are population patch measurements in which the av-  
119 erage of the current across many cells is determined. Hence the word ob-  
120 servation is used for a single concentration response curve. There could be  
121 several observations on a certain day.

122 Human NaV1.5:

123 Comparisons between pre-drug peak transient inward currents at the first  
124 pulse and post-drug peak transient inward currents fifth pulse were used  
125 to determine the global inhibitory effect of the compound. Data were nor-  
126 malised to the high and low controls. Low controls were wells in which 100  
127  $\mu\text{M}$  tetracaine was added for the NaV1.5 blocker assay. High controls were  
128 wells in which only 1% DMSO was added for the NaV1.5 blocker assay. The  
129 normalised data were analysed by using ActivityBase software. The amount  
130 of NaV1.5 current inhibition observed at the fifth depolarising pulse after  
131 compound addition was expressed as a percentage of the peak current ob-  
132 served at the first pulse before compound addition and used to generate a  
133 global block concentration dose response.

134 hERG:

135 Data were normalised to the high and low controls. Low controls were  
136 wells in which 50  $\mu\text{M}$  Quinidine was added for the hERG blocker assay.  
137 High controls were wells in which only 1% DMSO was added for the hERG  
138 assay. The normalised data were analysed by using ActivityBase software.  
139 The amount of tonic block is calculated from peak (maximum tail current  
140 value). This value is amplitude of the peak tail current minus the steady  
141 state average value obtained at  $-50$  mV holding potential before the first  
142 voltage step to  $+40$  mV.

143 KCNQ1:

144 Data were normalised to the high and low controls. Low controls were wells  
145 in which an internal characterised full block compound was added for the  
146 KCNQ1 blocker assay. DMSO concentration in compound wells and high  
147 controls wells were only 0.25% for the KCNQ1 assay. The normalised data  
148 were analysed by using ActivityBase software. The current elicited at the  
149 end of the 50 mV pulse is normalised to that at the start of the pulse and  
150 normalised to control data.

151 For All Channels:

152 Concentration response data were derived using a four parameter concentration-  
153 effect curve fitting procedure.  $\text{pIC}_{50}$  values and Hill coefficients were deter-

154 mined from these inhibition curves.

### 155 **S.3.2 CaV1.2 FLIPR Screen**

#### 156 **Cell Preparation**

157 Human Embryonic Kidney-293 (HEK293) cells were stably transfected with  
158 the  $\beta 2a$  and the  $\alpha 2\delta 1$  subunits of CaV1.2 (L-type calcium channel). Cells  
159 were cultured in DMEM HAMS-F12 +10% FBS. Cells were grown and main-  
160 tained at 37°C in a humidified environment containing 5% CO<sub>2</sub>. 24 hours  
161 prior to assay media was removed and replaced with DMEM-F12 media  
162 supplemented with 10% FBS and containing 2.5% hIK and 5% alpha1C  
163 BacMam virus transduction reagents to the cell suspension. Cells with less  
164 than 80% confluency were detached from the T75 culture flask for passage  
165 and harvesting using TrypLE or Versene. Cells were resuspended in DMEM-  
166 F12 media supplemented with 10% FBS and seeded at 15,000 cells per well  
167 in clear-bottom, black-walled 384 well plates.

#### 168 **Experimental Protocol**

169 Human CaV1.2 fluorescence was measured before and after the addition of  
170 a depolarising addition of 400 mM KCl using a Molecular Devices 384 well  
171 fluorescent imaging plate reader (FLIPR).

172 Cell media was replaced with tyrodes salt solution supplemented with 20 mM  
173 HEPES, 11.9 mM NaHCO<sub>3</sub>, 2.5 mM probenecid, 0.01% Pluronic acid, 2.5  
174  $\mu$ M Fluo4-AM (a calcium sensitive fluophore) and 250  $\mu$ M Brilliant Black  
175 (quenching solution) at pH 7.4 and the cells were incubated at 37°C in a  
176 humidified environment containing 5% CO<sub>2</sub> for 60 minutes. Compounds  
177 were prepared as serial dilution concentration response curves in DMSO  
178 before being diluted in tyrodes medium immediately prior to assay. Cells  
179 were incubated for 15 minutes in the presence of tyrodes buffer containing  
180 compounds of interest. Cell plates containing compounds were placed inside  
181 the FLIPR and changes in fluorescence measured ( $\lambda_{ex}$ =488 nm,  $\lambda_{EM}$ =54  
182 nm) (Sullivan et al., 1999) before and after the addition of the depolarising  
183 solution.

#### 184 **Data Analysis**

185 The timecourse of fluorescence across each well of the plate was measured  
186 before and after stimulation, and the maximum, minimum and basal values  
187 were extracted for further analysis.

188 Blockade of the transient increase in fluorescence caused by the influx of  
189 calcium through the activated calcium channel was used to determine the  
190 global inhibitory effect of the compound. Data (maximum minus minimum  
191 divided by basal fluorescence value) were normalised to the high and low  
192 controls. Low controls were wells in which 1 mM nimodipine was added for  
193 the CaV1.2 blocker assay. High controls were wells in which only 1% DMSO  
194 was added for the CaV1.2 blocker assay. The normalised data were analysed  
195 by using ActivityBase (IDBS) software. Concentration response data were  
196 derived using a four parameter concentration-effect fitting procedure. pIC50  
197 values were determined from these inhibition curves.

### 198 **S.3.3 Screening using PatchXpress**

199 NaV1.5:

200 See (Donovan et al., 2011).

201 hERG:

202 See (Donovan et al., 2011).

203 CaV1.2:

#### 204 **Cell Preparation**

205 Flasks of continuously cultured cells were grown (medium descriptions can  
206 be found in Tables S5 and S6 below) at 37°C, 5% CO<sub>2</sub> and split when cells  
207 were between 35 and 75% confluency to retain surface channel expression.  
208 To harvest cells for experiments, all solutions were warmed to 37°C. Flasks  
209 to be harvested had their medium aspirated and 10 mL of no Ca<sup>2+</sup>, no Mg<sup>2+</sup>  
210 PBS (Invitrogen Corporation, Carlsbad, CA) added. The PBS was gently  
211 rolled over the cell layer then aspirated. 4 mL of a 1:5 solution of TrypLE  
212 (recombinant trypsin, Invitrogen Corporation, Carlsbad, CA) diluted in no  
213 Ca<sup>2+</sup>, no Mg<sup>2+</sup> PBS was added. The solution was gently rolled over the  
214 cell layer and allowed to sit for 90 seconds at room temperature. The flask  
215 was tapped to dislodge cells. Eight mL of medium was used to quench  
216 the harvesting agent. The resulting cell stock was pipetted up and down  
217 twice with a 5 mL pipette to break up any cell clumps. The cell stock was  
218 spun at 1000 rpm for 90 seconds, the supernate aspirated off and 4 mL of  
219 fresh medium was added. The cells mass was broken up gently with a 200  
220  $\mu$ L pipettor. Cells were placed in a 37°C incubator to allow the cells to  
221 recover from the harvest. After 10 minutes, the cells were removed from

222 the incubator and spun down at 1000 rpm for 90 seconds. The aspirate was  
223 removed and 2 mL of external assay buffer (assay buffer detailed in Tables  
224 S5 & S6, depending on the assay) added. The cell stock was broken with a  
225 200  $\mu$ L pipettor and spun at 1000 rpm for 60 seconds. The supernate was  
226 removed and 150 to 225  $\mu$ L of external buffer added. This cell stock was  
227 added to the PatchXpress for the experiment. This protocol was followed  
228 for all cell lines.

229 For experiments using frozen cell lines, thawing consisted of removing the  
230 cells from the -180°C freezer and putting the vial in a 37°C water bath for  
231 15-20 seconds. The thawed cell stock was added to a vial containing 8 mL  
232 warmed growth medium. The rest of the procedure follows the procedure  
233 for constantly cultured cells at the point of the first centrifuging step.

234 Cells were re-suspended in 100 to 300  $\mu$ L of external buffer (Table S5 and  
235 S6, depending on which assay is being run) and put into the PatchXpress.  
236 3.5  $\mu$ L of stock was aliquoted to each well.

### 237 **Experimental Protocol**

238 Two command protocols were used for the CaV1.2 assay. For both versions  
239 of the CaV1.2 assay, each cell was clamped at a -90 mV holding potential.

240 In the earlier version, every thirty seconds a command protocol was deliv-  
241 ered consisting of ten depolarizing steps to +10 mV. Each step lasted ten  
242 milliseconds. The block was measured as the percent decrease in current  
243 measured at the tenth pulse. In the later version, a command pulse to zero  
244 millivolts was given every two seconds. The pulse lasted for 200 milliseconds  
245 with the peak inward current measured at each pulse.

246 In concentration-response experiments for all PatchXpress experiments, each  
247 solution was added three times (40  $\mu$ L each addition for 120  $\mu$ L total, 11  
248 seconds apart). After the addition, the compound was given 5 minutes to  
249 reach steady-state block. If after 5 minutes, the difference in peaks between  
250 sweeps was less than 0.1%, the next concentration was given, otherwise, the  
251 cell was allowed up to three more minutes to reach steady-state block before  
252 the next concentration addition.

253 At the end of each dose-response series, a negative control of external buffer  
254 with an identical amount of DMSO (vehicle) was added to wash off the  
255 compound effect. After this, a positive control was given to completely  
256 block the current (50  $\mu$ M cadmium).

### 257 **Data Analysis**



258 Data analysis for PatchXpress data was done using DataXpress, v2.0.4.5,  
 259 raw data from this program was compiled using Microsoft Excel and fitted  
 260 to a four parameter fit using GraphPad Prism v5.0. The four parameter fit  
 261 used to curve fit for the voltage dependence of activation was,

$$262 \quad Y = Y_{\min} + \frac{(Y_{\max} - Y_{\min})}{(1 + 10^{\exp((\log(EC50) - X) \cdot Hillslope)})}$$

Table S5: **Composition of culture medium for CaV1.2 $\beta$ 2 $\alpha$ 2 $\delta$ 1 expressing HEK293 cells used in PatchXpress screen of CaV1.2 channels.**

Chemical	Catalog # (manufacturer)	[stock]	[final]	lot #	mL
Dulbecco's modified eagle medium/F12 Ham's	11330-032 (Invitrogen)	100%	–	1344957	869
Fetal bovine serum	10437-028 (Invitrogen)	100%	10%	13558888	100
Glutamine	25030-149 (Invitrogen)	200 nM	2 mM	1318770	10
Puromycin	P9620-10ML (Sigma)	10 mg/mL	0.625 $\mu$ g/mL	106K4072	0.0625
Non-essential amino acids	11140-050 (Invitrogen)	10 nM (100x)	1%	1382464	10
G418/geneticin	10131-027 (Invitrogen)	50 mg/mL	400 $\mu$ g/mL	1387855	8
hygromycin B	10687-010 (Invitrogen)	50 mg/mL	100 $\mu$ g/mL	A8269	2

263 10  $\mu$ M nitrendipine needs to be added to the medium daily for passage of  
 264 cells to maintain viability. We make a 10 mM stock solution and aliquot it  
 265 into 200 mL batches to be added into a 200 mL medium batch for a final  
 266 concentration of 10  $\mu$ M. We currently use Tocris pharmaceuticals nitrendip-  
 267 ine, catalog number 0601, lot # 1A/73728.

268  
 269  
 270  
 271  
 272

Table S6: **Composition of internal solution for CaV1.2 used in PatchXpress screen of CaV1.2 channels.**

<b>Chemical</b>	<b>molecular weight</b>	<b>catalog #</b>	<b>mM</b>	<b>grams /0.25L</b>
Cesium methane sulfonate	228.0	C1426	108	6.156
HEPES	238.31	H3375	24	1.430
EGTA	468.3	E8145	10	1.171
MgCl <sub>2</sub>	95.22	M8266	4.5	1125 $\mu$ L of 1 M stock
CaCl <sub>2</sub>	147.0	C5080	0.1	250 $\mu$ L of 100 mM stock
ATP (disodium salt)	551.1	A2383	4	0.551
GTP (disodium salt)	523.2	G8877	0.3	0.039
creatine	131.14	C7080	5	0.164
phosphocreatine (disodium)	453.38	P1937	5	0.567
pyruvate (free acid)	88.06	15940 (Fluka)	5	86.68 $\mu$ L
Oxalacetate	132.07	171255 (Aldrich)	5	0.165

273 Initial pH should be  $\sim 4.89$ . Adjust to 7.30 using CsOH. Adjust osmolality  
274 to 295-300 mOsm.

## 275 **References**

- 276 Donovan, B., Bakshi, T., Galbraith, S., Nixon, C., Payne, L., & Martens, S.  
277 (2011). Utility of Frozen Cell Lines in Medium Throughput Electrophys-  
278 iology Screening of hERG and NaV1.5 Blockade. *Journal of Pharmaco-*  
279 *logical and Toxicological Methods*, *64*, 269–276.
- 280 Sullivan, E., Tucker, E., & Dale, I. (1999). Measurement of [Ca<sup>2+</sup>] Using  
281 the Fluorometric Imaging Plate Reader (FLIPR). In D. Lambert (Ed.),  
282 *Calcium Signaling Protocols* (pp. 125–133). Humana Press volume 114 of  
283 *Methods in Molecular Biology*. doi:10.1385/1-59259-250-3:125.